Novaliq Announces First Patient Randomized in Its ESSENCE Phase 2b/3 Trial of CyclASol® for the Treatment of the Signs and Symptoms of Dry Eye Disease

HEIDELBERG, Germany--(BUSINESS WIRE)--#CyclASol--Novaliq has begun randomization of patients in its ESSENCE Phase 2b/3 clinical trial evaluating CyclASol for the treatment of dry eye disease.

Full Story →